RxDoctor Payments Data

Raymond Hui, MD

Family Medicine · Middletown, NYNPI 1699865618

Payments from drug & device makers

$3,473in general payments, 2019–2025

Across 120 payments — averaging $28.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$903
  • Amarin Pharma, Inc.$802
  • Lilly USA, LLC$439
  • Novartis$396
  • AstraZeneca$266
  • Boehringer Ingelheim$162
  • plus $504 from 8 others

What the payments were for

  • Food & beverage$3,461100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,473 in reported general payments places this provider in the 80th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$272,904
Medicare patients
466
Services billed
12,612

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol96$146,103
MounjaroTirzepatide63$85,223
VascepaIcosapent Ethyl64$55,319
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$49,152
OzempicSemaglutide37$48,635
Repatha SureclickEvolocumab33$44,369
RybelsusSemaglutide25$42,357
EliquisApixaban44$41,255
TradjentaLinagliptin29$29,985
JardianceEmpagliflozin17$24,105
Repatha SyringeEvolocumab14$22,425
Icosapent Ethyl52$22,325
TrulicityDulaglutide13$21,496
Ezetimibe323$13,231
NexletolBempedoic Acid14$12,101

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$266$146,10396 claims
Lilly USA, LLCMounjaro, Trulicity$439$106,71976 claims
Novo NordiskOzempic, Rybelsus$63$90,99262 claims
Boehringer IngelheimTradjenta, Jardiance$162$54,09046 claims
GSKTrelegy Ellipta$118$49,15230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,321 family medicine providers in New York.

Other family medicine in Middletown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →